Small-cell lung cancer grows fast and often returns quickly after treatment. This study looked at what happens after the initial chemotherapy rounds are done. Researchers gave 21 patients these two new drug combinations to see if they could keep the cancer away longer. The first group took tislelizumab plus sitravatinib, while the second took tislelizumab plus anlotinib. Both groups had already received standard chemotherapy before starting these new drugs.
The results showed some hope. Patients on the first combination remained free of cancer progression for an average of 6.4 months. Those on the second combination lasted 7.8 months. Some patients in both groups had not progressed after one year. However, because these were small studies with only 18 patients in each group, we do not know if these numbers will hold true for everyone.
Safety was generally good. Most side effects were mild, and no patients died from the drugs themselves. The most common serious side effects were high blood pressure in the first group and tiredness in the second. Because these were single-arm studies without a direct comparison group, we cannot prove these drugs are better than what is already available. More large studies are needed to confirm if this approach truly helps more people.